Next Generation Imbruvica Performs Well For Acerta In Early Studies
This article was originally published in Scrip
Executive Summary
Acerta Pharma's second generation Bruton's tyrosine kinase (BTK) inhibitor, acalabrutinib (ACP-196), has proved itself to be a more selective, irreversible and improved version in early trials.
You may also be interested in...
Fast-To-Market Play For AstraZeneca's Acalabrutinib With MCL Filing
Never mind MYSTIC, AstraZeneca is pushing the spotlight onto its other oncology assets, and its second-generation BTK inhibitor has just been accepted for filing and given breakthrough status in the US.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.